Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

IGC Pharma (IGC) Accumulated Depreciation & Amortization (2016 - 2025)

IGC Pharma (IGC) has disclosed Accumulated Depreciation & Amortization for 14 consecutive years, with $1.7 million as the latest value for Q3 2025.

  • Quarterly Accumulated Depreciation & Amortization fell 33.99% to $1.7 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Sep 2025, down 33.99% year-over-year, with the annual reading at $2.7 million for FY2025, 10.28% up from the prior year.
  • Accumulated Depreciation & Amortization for Q3 2025 was $1.7 million at IGC Pharma, down from $2.8 million in the prior quarter.
  • The five-year high for Accumulated Depreciation & Amortization was $3.3 million in Q4 2021, with the low at $1.7 million in Q3 2025.
  • Average Accumulated Depreciation & Amortization over 5 years is $2.5 million, with a median of $2.6 million recorded in 2024.
  • The sharpest move saw Accumulated Depreciation & Amortization tumbled 45.82% in 2022, then surged 30.15% in 2023.
  • Over 5 years, Accumulated Depreciation & Amortization stood at $3.3 million in 2021, then tumbled by 45.82% to $1.8 million in 2022, then soared by 30.15% to $2.3 million in 2023, then increased by 11.77% to $2.6 million in 2024, then plummeted by 34.22% to $1.7 million in 2025.
  • According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods came in at $1.7 million, $2.8 million, and $2.7 million for Q3 2025, Q2 2025, and Q1 2025 respectively.